Biotech · Private company · Clarksville, MD, US
Neuronascent, Inc.
Track this companyFree. Adds Neuronascent, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- NNI-362Phase 1 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged VolunteersPHASE1 · COMPLETED · started Aug 1, 2019ClinicalTrials.gov NCT04074837 · fetched Nov 12, 2026
NIH awards2
- Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trialFiscal year 2024 · $350KNIH RePORTER 3U01AG082687-02S1 · fetched Nov 12, 2026
- Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trialFiscal year 2024 · $2.1MNIH RePORTER 5U01AG082687-02 · fetched Nov 12, 2026